510(k)

Step-by-step playbook for responding to FDA Additional Information requests in eSTAR 510(k) and De Novo submissions — response table format, file naming, version control, section mapping, RTA vs substantive deficiencies, and traceability to original submission sections.

A methodical approach to mining FDA's AI-enabled device list and 510(k) database for predicate devices — covering technological characteristic extraction, public summary limitations, weak predicate argument avoidance, and a complete predicate evaluation matrix.

Step-by-step guide to building the ASCA evidence package for 510(k) and De Novo submissions — ASCA Summary Test Report, declaration of conformity, lab accreditation status check, scope matching, withdrawn/suspended lab risk, FDA questions, and submission rescue strategies.

How to build the Unresolved Software Anomalies table for FDA premarket cybersecurity submissions — CVSS scoring, exploitability assessment, clinical impact analysis, compensating controls, SBOM linkage, VEX status, labeling language, release criteria, and common reviewer objections.

Practical due-diligence checklist for evaluating the FDA Third Party Review (3P510k) Program — product-code eligibility verification, Accredited Person selection, conflict-of-interest screening, eSTAR compatibility, FDA final-determination risk, timeline and cost tradeoffs, and when to avoid third-party review.

Decision tree for when a software or cybersecurity update can use Special 510(k) vs Traditional 510(k) — risk analysis, V&V summary, FDA guidance, and evidence package requirements.

Practical guide to the top 12 FDA cybersecurity deficiencies causing premarket submission holds in 2026 — SBOM gaps, threat modeling failures, risk assessment mistakes, and fixes aligned with the February 2026 final guidance and Section 524B.

Dedicated CLIA waiver playbook for IVD manufacturers — covering waived, moderate, and high complexity categories, CW submission content, flex studies, lay-user studies, the Dual 510(k) + CLIA Waiver pathway, review timelines, common deficiencies, and real-world examples.

U.S. Agent and Official Correspondent fees run $1,000–$5,000+/year on top of FDA's $11,423 annual establishment fee. A buyer-side breakdown of hourly, registration-fee-plus-annual, and flat all-inclusive pricing models — with 3-year cash flow scenarios for foreign manufacturers selling into the United States in 2026.

Comprehensive guide to the FDA Emergency Use Authorization (EUA) pathway for medical devices under Section 564 of the FD&C Act — legal basis, CBRN emergency triggers, statutory criteria, submission process, EUA vs 510(k)/PMA comparison, post-COVID transition framework, and current active EUAs.

Comprehensive guide to FDA medical device establishment registration and device listing under 21 CFR Part 807 — FURLS/DRLM system walkthrough, FY 2026 fees ($11,423), who must register, annual renewal process, common violations, and step-by-step instructions.

Comprehensive guide to the FDA eSTAR electronic submission template for 510(k) and De Novo submissions — mandatory requirements since October 2023, template structure, section-by-section walkthrough, completeness verification, submission methods, and common mistakes to avoid.

Comprehensive guide to FDA export certificates for medical devices — Certificate to Foreign Government (CFG), Certificate of Exportability (COE), CECATS application process, fees, eligibility criteria, common mistakes, and step-by-step instructions for global market access.

How much does medical device registration cost in 30+ countries? Side-by-side comparison of government fees, total project costs, and timelines across the US, EU, Brazil, Japan, South Korea, India, China, Saudi Arabia, UK, Australia, Canada, Singapore, and more.

A practical regulatory strategy guide for medical device startups — covering FDA pathway selection, budget planning, Q-Sub pre-submissions, eSTAR templates, QMSR compliance, fundraising alignment, and the programs that accelerate market entry in 2026.

Strategic analysis of dual CE Mark + FDA 510(k)/PMA approval showing the multiplier effect across 25+ markets, country grouping matrix, and concrete cost/timeline comparisons for manufacturers pursuing both pathways.

Data-driven analysis of FDA 510(k) clearance rates, RTA hold rates, NSE decisions, and the most common reasons submissions fail — with actionable strategies to maximize your chances of first-cycle clearance in 2026.

Everything you need to know about FDA medical device user fees for FY 2026 (October 2025–September 2026) — covering the complete MDUFA V fee schedule, small business determination program, first PMA waiver, new establishment registration fee waiver, year-over-year comparisons, and strategies to minimize your regulatory costs.

A practical guide to evaluating and selecting a medical device regulatory consultant — covering key criteria, questions to ask, red flags to avoid, pricing benchmarks, certifications (RAC, RAPS), and a decision framework for companies at every stage.

A data-driven breakdown of every cost component in a 510(k) submission — FDA user fees, testing, consulting, and hidden expenses — with 2026-specific figures and cost-saving strategies for small businesses.